| Storage Buffer | PBS pH 7.4 |
| Storage Temperature | -80ºC |
| Shipping Temperature | Dry Ice. Shipping note: Product will be shipped separately from other products purchased in the same order. |
| Purification | Ion-exchange Purified |
| Cite This Product | Human Recombinant Alpha Synuclein E83Q Mutant Pre-formed Fibrils (StressMarq Biosciences | Victoria, BC CANADA | Catalog# SPR-539) |
| Certificate of Analysis | Starting monomers are certified > 95% pure via SDS-PAGE and A260/A280 ratio |
| Other Relevant Information | For corresponding monomers, see Catalog # SPR-538. |
| Alternative Names | Alpha Synuclein E83Q, Alpha-Synuclein E83Q, α synuclein E83Q, E83Q synuclein, Alpha Synuclein E83Q mutant, SNCA E83Q mutation, Alpha Synuclein NAC mutation E83Q, SNCA E83Q Aggregated Protein, Seeding‑Competent Alpha‑Synuclein E83Q Fibrils |
| Research Areas | Neurodegeneration, Neuroscience, Parkinson's Disease, Synuclein |
| Swiss Prot | P37840 |
| Scientific Background | Alpha Synuclein E83Q is a rare missense variant of the SNCA gene, in which glutamate is replaced by glutamine at residue 83 within the non-amyloid-β component (NAC) region, a sequence central to alpha-synuclein aggregation and fibril formation. E83Q was initially identified in a patient presenting with parkinsonism, progressive non-amnestic dementia, severe frontotemporal atrophy, and extensive cortical Lewy body pathology in the absence of tau or TDP-43 pathology. Subsequent biochemical, structural, cellular, and neuronal studies demonstrated that E83Q markedly accelerates alpha-synuclein fibrillization, produces fibrils with altered structural and dynamic properties, and is associated with increased alpha-synuclein accumulation, Ser129 phosphorylation, cellular toxicity, neuronal fibril uptake, and seeding activity relative to wild-type alpha-synuclein. StressMarq’s Human Recombinant Alpha Synuclein E83Q Mutant Monomers have been demonstrated to self-aggregate readily and form pre-formed fibrils (PFFs) that exhibit reduced Thioflavin T (ThT) binding relative to PFFs formed by wild-type alpha synuclein. |
| References |
1. Kapasi, A., Brosch, J. R., Nudelman, K. N., Agrawal, S., Foroud, T. M., & Schneider, J. A. (2020). A novel SNCA E83Q mutation in a case of dementia with Lewy bodies and atypical frontotemporal lobar degeneration. Neuropathology, 40, 620–626. DOI: 10.1111/neup.12687 2. Kumar, S. T., Mahul-Mellier, A.-L., Hegde, R. N., Rivière, G., Moons, R., Ibáñez de Opakua, A., Magalhães, P., Rostami, I., Donzelli, S., Sobott, F., Zweckstetter, M., & Lashuel, H. A. (2022). A NAC domain mutation (E83Q) unlocks the pathogenicity of human alpha-synuclein and recapitulates its pathological diversity. Science Advances, 8(17), eabn0044. DOI: 10.1126/sciadv.abn0044 3. Magalhães, P., & Lashuel, H. A. (2022). Opportunities and challenges of alpha-synuclein as a potential biomarker for Parkinson’s disease and other synucleinopathies. npj Parkinson’s Disease, 8, 93. DOI: 10.1038/s41531-022-00357-0 |
Sedimentation assay on Alpha Synuclein E83Q Mutant Pre-Formed Fibrils (Cat # SPR-539). Samples were spun down at 15,000 x g, washed, and then spun down again. Fibril samples are prepared in denaturing conditions prior to running on the gel. SDS-PAGE analysis on a 12% Bis-Tris gel shows that the majority of the fibril is insoluble.
In vitro seeding activity of Alpha Synuclein E83Q Mutant Pre-Formed Fibrils in a Thioflavin T (ThT) assay. Alpha Synuclein E83Q Mutant Pre-Formed Fibrils (Cat # SPR-539) seed fibril formation of Alpha Synuclein E83Q Mutant Monomers (Cat # SPR-538) over 72 hours. Reactions (100uL) shaken at 600 rpm in Greiner-Bio 96 Well Non-Binding Cell Culture Microplates, Black (Greiner-Bio Catalog #655900) at 37oC in the presence of 25 uM ThT and read with an XPS Microplate Reader set at 450nmex/485nmem.
Reviews
There are no reviews yet.